Liver targeting of plasmid DNA by pullulan conjugation based on metal coordination

Journal of Controlled Release

Volumn 83, Issue 2, 2002, Pages 287-302

  Hosseinkhani, Hossein ^a   Aoyama, Teruyoshi ^a,b   Ogawa, Osamu ^b   Tabata, Yasuhiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Enhanced gene expression; Liver targeting; Metal coordination; Plasmid DNA; Pullulan conjugation

Indexed keywords

ACETIC ACID DERIVATIVE; ALBUMIN; ARABINOGALACTAN; CHELATE; DIETHYLENETRIAMINE; METAL; PLASMID DNA; POLYSACCHARIDE; PULLULAN; SPERMINE; TRIENTINE; ZINC ION;

ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETIC TRANSFECTION; LIVER; LIVER CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; DNA; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; GLUCANS; LIVER; MALE; METALS, HEAVY; MICE; PLASMIDS;

EID: 0037020495     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00201-8     Document Type: Article

References (60)

1. Mahato R.I., Takakura Y., Hashida M. Non-viral vectors for in vivo gene delivery: physicochemical and pharmacokinetic considerations. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;133-172.
2. Tomlinson E., Rollan A.P. Controllable gene therapy: pharmaceutics of non-viral gene delivery systems. J. Controlled Release. 39:1996;357-371.
3. Ledley F.D. Non-viral gene therapy: the promise of genes as pharmaceutical products. Hum. Gene Ther. 6:1995;1129-1144.
4. Ledley F.D. Pharmaceutical approach to somatic gene therapy. Pharm. Res. 13:1996;1595-1614.
5. Mahato R.I., Takakura Y., Hashida M. Development of targeted delivery systems for nucleic acid drugs. J. Drug Targeting. 4:1997;337-357.
6. Kabanov A.V., Felgner P.L., Seymour L.W., Self-assembling Complexes For Gene Delivery. From Laboratory To Clinical Trial. 1998;Wiley, New York.
7. Kabanov A.V., Kabanov V.A. DNA complexes with polycations for the delivery of genetic material into cells. Bioconjug. Chem. 6:(1):1995;7-20.
8. Cotton M., Wagner E. Non-viral approaches to gene therapy. Curr. Opin. Biotechnol. 4:(6):1993;705-710.
9. Abdallah B., Sachs L., Demeneix B.A. Non-viral gene transfer: applications in developmental biology and gene therapy. Biol. Cell. 85:(1):1995;1-7.
10. Pouton C.W., Seymour L.W. Key issues in non-viral gene delivery. Adv. Drug Deliv. Rev. 34:1998;3-19.
11. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12:1995;825-830.
12. Lew D., Parker S.E., Latimer T., Abai A.M., Kuwahara-Rundell A., Doh S.G., Yang Z., Laface D., Gromkowski S.H., Nabel G.I., Manthorpe M., Norman J. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum. Gene Ther. 6:1995;553-564.
13. Yu L., Suh H., Koh J.J., Kim S.W. Systemic administration of terplexDNA syatem: pharmacokinetics and gene expression. Pharm. Res. 18:(9):2001;1277-1283.
14. Kircheis R., Blessing T., Brunner S., Wightman L. Tumor targeting with surface-shielded ligand-polycation DNA complexes. J. Controlled Release. 72:2001;165-170.
15. Liu F., Huang L. Development of non-viral vectors for systemic gene delivery. J. Controlled Release. 78:2002;259-266.
16. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 267:1992;18759-18765.
17. Senior J. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta. 1062:1991;77-82.
18. Mori A., Klibanov A.L., Torchilin V.P., Huang L. Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposome and on the target binding of immunoliposomes in vivo. FEBS Lett. 284:1991;263-266.
19. Torchilin V.P. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim. Biophys. Acta. 1195:1994;181-184.
20. Woodle M.C., Engbers C.M., Zalipsky S. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 5:1994;493-496.
21. Liu Y. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 15:1997;167-173.
22. Li S., Huang L. In vivo gene transfer via intravenous administration of cationic lipid protamine DNA (LPD) complexes. Gene Ther. 4:1997;891-900.
23. Templeton N.S. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15:1997;647-652.
24. Ogris M., Brunner S., Schuller S., Kircheis R., Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6:1999;595-605.
25. Budker V., Budker T., Zhang G., Subbotin V., Loomis A., Wolff J.A. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J. Gene Med. 2:2000;76-88.
26. Kaneda Y., Iwai K., Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 243:1989;357-378.
27. Grossman M. Successful ex vivo gene transfer into hepatocytes in vivo. Nat. Genet. 6:1994;335-341.
28. G.Y. Wu, C.H. Wu, Gene therapy by targeting nucleic acids to hepatocytes, in I.M. Arias et al. (Ed.), The Liver: Biology and Pathobiology, 3rd Edition, Raven Press, New York, 1994, pp. 1537-1556.
29. Wilson J.M. Round two for liver gene therapy. Nat. Genet. 12:1996;232-233.
30. Nishikawa M., Yamauchi M., Morimoto K., Ishida E., Takakura Y., Hashida M. Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with sythetic multi-functional gene delivery system. Gene Ther. 7:2000;548-555.
31. Perales J.C. Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor. J. Biol. Chem. 272:1997;7398-7407.
32. Nishikawa M. Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly (L-lysine) complexes by controlling their physicochemical properties. J. Pharmacol. Exp. Ther. 287:1998;408-415.
33. Hashida M. Targeted delivery of plasmid DNA complexed with galactosylated poly (L-lysine). J. Controlled Release. 53:1998;301-310.
34. Nishikawa M. Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. Int. J. Pharm. 85:1992;75-85.
35. Wu G.Y., Wu C.H. Receptor-mediated in vitro gene transfection by a soluble DNA carrier complexes. J. Biol. Chem. 262:1996;4429-4432.
36. Wu G.Y., Wu C.H. Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263:1991;14621-14624.
37. Stankovics J., Crane A.M., Andrews E., Wu C.H., Wu G.Y., Ledley F.D. Overexpression of human methylmalonyl CoA mutase in mice after in vivo gene transfer with asialoglycoprotein/polylysine/DNA complexes. Hum. Gene Therapy. 5:1994;1095-1104.
38. Kwoh D.Y., Coffin C.C., Lollo C.P., Jovenal J., Banaszczyk M.G., Mullen P., Phillips A., Amini A., Fabrycki J., Bartholomew R.M., Brostoff S.W., Carlo D.J. Stabilization of poly-L-lysine/DNA polylplexes for in vivo gene delivery to the liver. Biochim. Biophys. Acta. 1444:1999;171-190.
39. Zanta M.A., Boussif O., Adib A., Behr J.P. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug. Chem. 8:1997;839-844.
40. Bettinger T., Remy J.S., Erbacher P. Size reduction of galactosylated PEI/DNA complexes improves lectin-mediated gene transfer into hepatocytes. Bioconjug. Chem. 10:(4):1999;558-561.
41. Lim D.W., Yeom II Y., Park T.G. Poly(DMAEMA-NVP)-b-PEG-galactose as gene delivery vector for hepatocytes. Bioconjug. Chem. 11:2000;688-689.
42. Nishikawa M., Yamauchi M., Morimoto K., Ishida E., Takakura Y., Hashida M. Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. Gene Ther. 7:2000;548-555.
43. Kaneo Y., Tanaka T., Nakano T., Yamaguchi Y. Evidence for receptor-mediated hepatic uptake of pullulan in rats. J. Controlled Release. 70:2001;365-373.
44. Yamaoka T., Tabata Y., Ikada Y. Body distribution profile of polysaccharides after intravenous administration. Drug Deliv. 1:1993;75-82.
45. Yamaoka T., Tabata Y., Ikada Y. Comparison of body distribution of poly (vinyl alcohol) with other water-soluble polymers after intravenous administration to mice. J. Pharm. Pharmacol. 47:1995;479-486.
46. Xi K., Tabata Y., Uno K., Yoshimoto M., Kishida T., Sokawa Y., Ikada Y. Liver targeting of interferon through pullulan conjugation. Pharm. Res. 13:1996;1846-1850.
47. Suginoshita Y., Tabata Y., Moriyasu F., Ikada Y., Chiba T. Liver targeting of interferon-β with a liver-affinity polysaccharide based on metal coordination in mice. J. Pharmacol. Exp. Ther. 298:(2):2001;805-811.
48. Tabata Y., Noda Y., Matsui Y., Ikada Y. Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination. J. Controlled Release. 59:1999;187-196.
49. Kircheis R., Wightman L., Schreiber A., Robitza B., Rossler V., Kursa M., Wagner E. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8:2001;28-40.
50. Tabata Y., Matsui Y., Uno K., Sokawa Y., Ikada Y. Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver. J. Interferon Cytokine Res. 197:1999;287-292.
51. Hogfeldt E., Stability constants of metal-ion complexes part A: Inorganic ligands, IUPAC chemical data series. No. 21:1982;Pergamon Press, New York.
52. Jia X., Marzilli L.G. Zinc ion-DNA polymer interactions. Biopolymers. 31:1991;23-44.
53. Litzinger D.C., Ransone C.M., Ralph L.D., Laderach W., Whitcomb K.L., Woodward M.A., Niven R.W., Treuheit M.J. A method for preparing chelate-cytokine conjugates with retention of protein structure, biological activity, and pharmaco-kinetic properties. J. Immunol. Methods. 187:1995;151-161.
54. Odonmazig P., Ebringerova A., Machova E., Alfoldi J. Structural and molecular properties of the arabinogalactan isolated from Mongolian larchwood. Carbohydr. Res. 252:1994;317-324.
55. Groman E.V., Enriquez P.M., Jung C., Josephson L. Arabinogalactan for hepatic drug delivery. Bioconjug. Chem. 5:(6):1999;547-556.
56. Kaneo Y., Ueno T., Tanaka T., Iwase H., Yamaguchi Y., Uemura T. Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. Int. J. Pharm. 201:2000;59-69.
57. Magnusson S., Berg T. Extremely rapid endocytosis mediated by the mannose receptor of sinsusoidal endothelial rat liver cells. Biochem. J. 257:1989;651-656.
58. Jansen R.W., Molema G., Ching T.L., Oosting R., Harms G., Moolenaar F., Hardonk M.J., Meijer D.K.F. Hepatic endocytosis of various types of mannose-terminated albumines. J. Biol. Chem. 266:(5):1991;3343-3348.
59. 65. Fed. Proc. 9:1950;260.
60. Kimoto T., Shibuya T., Shiobara S. Safety studies of a novel starch, pullulan: chronic toxicity in rats and bacterial mutagenicity. Food Chem. Toxicol. 35:1997;323-329.